EPZM

Epizyme Inc.

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$322.1M

Burn Rate (Qtr)

$56.1M

Company Profile

Epizyme’s vision is to rewrite treatment for cancer and other serious diseases through novel epigenetic medicines. We aspire to change the standard of care for patients and physicians by developing medicines with fundamentally new mechanisms of action.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Tazverik (Tazemetostat )

Non-Hodgkins Lymphoma

Quarterly Sales (Approved)

February 26, 2021

Tazverik (tazemetostat)

Epithelioid Sarcoma

Quarterly Sales (Approved)

February 26, 2021 (Est)

Recent Posts

See what the community is saying - click to see full post

EPZM - Epizyme Reports Business Progress and Third Quarter 2020 Financial Results

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon